Page 8 - Andreas Muehler News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EQS-News: Immunic, Inc : Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

Issuer: Immunic, Inc. / Key word(s): Conference/Study Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

United statesSan diegoValentina sciaccaPaula schwartzEdna kaplanDennis riedlMatej ondrusChristian wolfDaniel vittJessica breuRobertj foxAndreas muehlerMellen centerAmericas committee for treatmentRx communications groupDistribution services

EQS-News: Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

Issuer: Immunic, Inc. / Key word(s): Miscellaneous Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need 09.02.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Host Virtu.

Edna kaplanHella kohlhofMichael schumannPaula schwartzBenjamin franklinDaniel vittJessica breuAndreas muehlerJosepha murrayDepartment of internal medicineShirley berry professor of gastrointestinal sciencesDivision of gastroenterologyDepartment of gastroenterologyRx communications groupDistribution servicesCeliac disease research

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused.

Edna kaplanHella kohlhofMichael schumannPaula schwartzBenjamin franklinDaniel vittJessica breuAndreas muehlerJosepha murrayDepartment of internal medicineShirley berry professor of gastrointestinal sciencesDivision of gastroenterologyDepartment of gastroenterologyRx communications groupPrnewswire immunic incCeliac disease research

Immunic (IMUX) Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium

Immunic (IMUX) Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesHella kohlhofLawrence steinmanSteinmanl epstein barrHeinz wiendlLarry steinmanFred lublinDaniel vittAndreas muehlerFredd lublinInstitute of translational neurologyDepartment of neurologyUniversity of muStanford university school of medicineNeurological sciences

EQS-News: Immunic, Inc : Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug s Neuroprotective Potential

Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting

New yorkUnited statesPaula schwartzLawrence steinmanEdna kaplanHella kohlhofSteinmanl epstein barrHeinz wiendlLarry steinmanFred lublinDaniel vittJessica breuAndreas muehlerFredd lublinInstitute of translational neurologyDepartment of neurology